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Abstract  
Objective: To compare the effect of rice bran oil versus statins (atorvastatin drug) on blood 
glucose, glycosylated hemoglobin (HbA1C) and serum lipid profiles in patients with type 2 diabetes. 
The safety of the tested rice bran oil and atorvastatin were investigated. Fatty acids contents of 
RBO, olive and sesame oil were also assessed. 
Materials and Methods: Forty four eligible patients with type 2 diabetes and moderately 
hyperlipidemic were randomly and equally allocated into two groups, rice bran oil (RBO) group and 
atorvastatin group. The RBO group received a low-calorie diet and consumed 30 g / day RBO oil as 
salad dressing and for use as main cooking oil for 6 months. The Atorvastatin group received a low-
calorie diet and 40 mg/day of atorvastatin drug for 6 months. At baseline and after 6 months of 
study intervention, blood glucose, glycosylated hemoglobin (HbA1c), serum lipid profiles; hepatic, 
renal and inflammatory biomarkers were estimated. 
Results: Results showed significant increase in fasting and postprandial blood glucose, HbA1C 
and liver transaminases (alanine transaminase ALT and aspartate transaminase AST) in the 
atorvastatin group while a significant reduction was shown in RBO group. Moreover, significant 
reductions in lipid profile levels, blood urea, serum uric acid and erythrocyte sedimentation rate 
(ESR) were observed in both RBO and atorvastatin groups after 6 months of the study intervention.  
Conclusion: The use of rice bran oil together with dietary modifications may have implications in 
lowering fasting and postprandial blood glucose, suppressing serum lipid levels, reduce the 
TC/HDL-C ratio and therefore reducing the risk of cardiovascular disease. Moreover, RBO exerts a 
hypouricemic action and anti-inflammatory effects. The findings obtained from the current study 
reinforce the use of RBO as an alternative natural potent hypolipidemic agent safer than 
atorvastatin drug that may induce side effects in some cases in patients intolerant to statins. 
 
 
Introduction 
The increasing worldwide prevalence of 
diabetes mellitus increases the risk of heart disease 
and stroke. This will substantially increase burden of 
cardiovascular death rate morbidity and mortality due 
to atherosclerotic heart disease [1]. The World Health 
Organization (WHO) estimates that CVD will continue 
to dominate mortality trends in the future and in 2015, 
there will be about 20 million CVD deaths [2].  
Type 2 diabetes is characterized by insulin 
resistance and often accompanied with cardiovascular 
risk factors, including dyslipidemia, obesity and 
hypertension. The 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors (statins) 
are the most potent class of drugs used as lipid-
lowering agents. Statins have been shown to 
decrease the mortality from coronary artery disease 
and decrease the incidence of myocardial infarction, 
stroke and peripheral vascular disease [3].  
Several clinical trials have been made to 
emphasize the safety and tolerability of statins. The 
most important adverse effects associated with statins 
are asymptomatic increases in liver transaminases [4] 
and myopathy [5]. Besides, other adverse effects 
associated with statin therapy are relatively mild and 
often rare [6]. Regarding these adverse effects and 
high cost of this class of drugs, many statin-intolerant 
patients seek alternative lipid-lowering therapies to 
manage their dyslipidemia.  
Dietary oil intake has an important influence 
on blood lipid concentrations [7]. Rice bran oil (RBO), 
an unconventional oil is recently introduced onto the 
Egyptian market for human use. It is believed to be a 
healthy vegetable oil in Asian countries.  It is 
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characterized by a balanced fatty acids meeting 
American Heart Association (AHA) recommendations. 
It exerts hypolipidemic activity in relation to more 
commonly used vegetable oils rich in linoleic acid [8]. 
Many researches suggested that rice bran oil’s 
cholesterol-lowering properties are explained by its 
unsaponifiable components with nutraceutical value 
more than by its fatty acid composition [9]. The 
unsaponifiable fractions mainly composed of 
phytosterols (γ-oryzanol), triterpene alcohols, 
tocopherols and tocotrienols have high antioxidant 
property [10]. In addition, RBO contains up to 20% 
saturated fatty acids (SFA) and equal amounts of 
monosaturated fatty acids (MUFA) and polysaturated 
fatty acids (PUFA) [11]. 
Rice bran oil has performance properties 
competitive to other widely used oils. Its taste and 
performance is complementary to salad, cooking, and 
frying applications as it has a high smoke point [12]. 
The aim of this study was to compare the 
effect of rice bran oil versus atorvastatin drug on blood 
glucose, glycosylated hemoglobin and serum lipid 
profiles in patients with type 2 diabetes. The safety of 
the tested rice bran oil and atorvastatin were studied. 
Fatty acids content of RBO, olive and sesame oil were 
also assessed. 
 
Materials and Methods 
Subjects 
A total of 44 eligible patients with type 2 
diabetes and moderately hyperlipidemic aged 40–60 
years old were recruited into the study for a 6 months 
trial. Diabetic duration was of 6-10 years. The study 
subjects had an initial baseline serum fasting blood 
glucose   150 mg/dl with no acute complications, 
serum TC  220 mg/dl, LDL  137 mg/dl and TG  
204 mg/dl. Subjects had no evidence of any chronic 
illness including hepatic, renal, thyroid or cardiac 
dysfunction. Exclusion criteria included extreme 
dietary habits such as vegetarianism, severely low fat 
intake and extreme levels of physical activity. The 
protocol of the study was approved by the National 
Research Centre Ethics Committee. In addition an 
informed consent was obtained from each participant 
to be included in the study. 
 
Experimental design 
This was a randomized, comparison study. 
Forty four subjects were randomly allocated into two 
groups, rice bran oil (RBO) group and atorvastatin 
group. All subjects received a low-calorie diet, 1400 
Kcal energy per day for six months, including 26% fat, 
17% proteins, and 57% carbohydrates. The 
atorvastatin group received the low-calorie diet and 40 
mg/day of atorvastatin drug daily for 6 months. 
Subjects in this group were under an antidiabetic 
regimen of drug (Glucophage). The RBO group 
received the low-calorie diet and consumed 30 g / day 
RBO oil as salad dressing and for use as main 
cooking oil for 6 months. Subjects in this group were 
not taking any medication known to affect blood 
glucose or plasma lipid levels (lipid lowering drugs, B-
blockers or diuretics).  The rice bran oil was produced 
by the Thai Ideal Oil Limited Company, Bangkok, 
Thailand. The rice bran oil used had an ISO 
9001:2008. Both groups received identical lifestyle 
education and a therapeutic lifestyle change with 
some diet restrictions in fat intake. Butter and 
margarine were strictly avoided. Adherence to the 
dietary recommendations was assessed by collecting 
two 24-hour diet recalls at baseline and after 6 
months. During the study period, the dietary intake 
data were analyzed using Nutrisurvey 5, version 2007 
to calculate the consumption of calories and the 3 
major macronutrients.  
The RBO, olive oil and sesame oil were 
evaluated and compared for fatty acids composition. 
 
Blood sampling and biochemical analysis 
Blood samples were drawn after a 12- hours 
overnight fasting to test the biochemical 
measurements at baseline and after 6 months of the 
intervention period. Part of the blood samples were 
collected in tubes containing EDTA for quantitative 
colorimetric determination of glycosylated hemoglobin 
(HbA1C) using ion exchange resin by Stanbio 
Laboratory (USA) [13]. The remaining blood samples 
were allowed to clot for 20 min., centrifuged at 4000 
rpm for 15 min. to separate the serum.  
Fasting and postprandial blood glucose were 
determined in the fresh serum by using oxidase 
peroxidase method as described by Trinder [14].  The 
rest of the serum was stored at - 20
o
C until used for 
further analysis of lipid profile, liver function and 
kidney function tests. 
Serum total cholesterol (TC), high-density 
lipoprotein cholesterol (HDL- C) and triglycerides (TG) 
were determined enzymatically using commercially 
available kits by Stanbio (USA) as described by Allain 
et al., [15], Lopes-Virella et al., [16] and Buccolo and 
David, [17] respectively. Serum low-density lipoprotein 
cholesterol (LDL-C) and very low density lipoprotein 
cholesterol (VLDL-C) were subsequently estimated 
using Friedewald formula [18]: 
LDL = TC - HDL - TG/5 (mg/dL) 
VLDL = TG ÷ 5 (mg/dL) 
TC/ HDL- C ratio was also calculated. 
Hepatic biomarkers, including aspartate 
aminotransferase (AST), alanine aminotransferase 
(ALT) were determined according to the colorimetric 
method described by Reitman and Frankel [19]. 
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Renal function biomarkers including serum 
creatinine, blood urea nitrogen (BUN) and serum uric 
acid were determined using commercially available 
kits by Stanbio (USA) as described by Fabinay and 
Eringhausen, [20], Patton and Grouch, [21] and Rebar 
et al., [22] respectively.   
Inflammatory biomarker erythrocyte 
sedimentation rate (ESR) was also determined in 
blood samples as described by Bull et al., [23].    
 
Assessment of fatty acids in vegetable oils  
Fatty acid methyl esters of the vegetable oils 
were prepared according to Sheppard and Iverson 
[24] to be subjected to Gas liquid chromatography 
(GLC) for fatty acids estimation. 
 
Fatty acids preparation 
Fatty acid methyl esters were prepared by 
treatment of vegetable oils by sulphuric acid/ 
methanol method.  
 
Identification of fatty acids methyl ester  
GLC analysis of the methyl esters was 
performed by using Konick equipped with a flame 
ionization detector (FID). A fused silica capillary 
column DB-5 (60 m x 0.32 mm. id,) was used. The 
oven temperature was maintained initially at 50°C for 
5 min., and then programmed from 50 to 250°C at a 
rate of 3°C/min. Helium was used as the carrier gas, 
at flow rate of 1.1 ml/min. The injector and detector 
temperatures were 220 and 250°C, respectively. The 
retention indices (Kovats indices) of the separated 
fatty acid methyl ester components were calculated 
using standard fatty acid methyl esters standard (C4-
C37, Sigma-Aldrich Co.) as references.  
 
Statistical analysis 
The data are presented as means ± SEMs. 
Statistical Package for the Social Sciences SPSS 
software for windows (SPSS Inc., Chicago, IL, version 
17.0) was used for the statistical analysis. Two 
independent sample t- test was used to compare 
baseline data between the RBO and atorvastatin 
groups and to compare percentage changes before 
and after the study intervention. Paired t-test was 
used to compare data from before and after the study 
intervention between the RBO group and the 
atorvastatin group. P-Value <0.05 indicated a 
statistically significant difference for all tests. 
 
Results 
Fatty acid profiles of rice bran oil vs olive oil 
and sesame oil are shown in Table 1. Rice bran oil 
had a higher proportion of total SFAs, specifically 
palmitic acid (16:0), than the other vegetable oils. Rice 
bran oil contained modest proportions of MUFAs and 
PUFAs, the percent distributions of which were 
intermediate between olive and sesame oil. Olive oil 
was relatively high in MUFAs, whereas sesame oil 
was relatively high in PUFAs. 
Table 1: Comparison of the percentage of fatty acids profile of 
rice bran oil vs olive oil and sesame oil. 
 
Fatty acids (%) 
Oils 
Rice Bran Olive Sesame 
C14:0 34.0 Trace _ 
C16:0 17.09 13.33 8.42 
C18:0 1.95 1.88 5.16 
C 20:0 0.67 Trace 0.93 
Σ SFA
1
 20.14 15.21 14.51 
C16:1 Trace 1.89 0.30 
C18:1 41.46 70.76 38.36 
C20:1 0.53 Trace _ 
ΣMUFA
1
 41.99 72.65 38.66 
C 18:2 36.58 11.16 43.99 
C18:3 1.29 1.02 0.60 
ΣPUFA
1
 37.87 12.18 44.59 
1
SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated 
fatty acid. 
 
The results of the dietary analysis are shown 
in Table 2. No significant differences in calorie 
intakes, macronutrient intakes, or macronutrient 
intakes as a percentage of calories were observed in 
a comparison of values before and after the study 
intervention between the two groups. 
Table 2: Average daily intake of energy, protein, fat and 
carbohydrate in 3-day dietary records in subjects during 
intervention periods.
1   
     
                                     Atorvastatin (n =22)                              RBO (n =22)        
After 6 
months 
Baseline 
After 6 
months 
Baseline  
1459.4 ± 75.6 1435.6 ± 90.5 1479.2 ± 68.3 1483.6 ± 70.2 Kcal/day 
67.2 ± 4.8 69.2 ± 5.3 70.2 ± 4.9 69.5 ± 6.6 Protein (g) 
58.1 ± 4.4 52.8 ± 3.4 53.0 ± 3.8 53.2 ± 4.3 Fat (g) 
164.0 ± 5.8 167.3 ± 6.6 176.1 ± 6.5 177.0 ± 7.5 CHO (g)
2
 
19.0 ± 1.8 20.0 ± 1.5 19.0 ± 1.3 19.0 ± 1.1 Protein (%E)
2
 
35.0 ± 3.1 33.0 ± 3.4 32.0 ± 2.7 32.0 ± 2.5 Fat (%E)
2
 
46.0 ± 2.2 47.0 ± 2.9 49.0 ± 2.5 49.0 ± 2.8 CHO (%E)
2
 
1
Values are expressed as mean ± SEM; 
2
 CHO, carbohydrate; %E, % of energy. 
 
Blood glucose, HbA1c and serum lipid levels 
are shown in Table 3. Baseline parameters did not 
differ significantly between the subjects assigned to 
the two groups. In Atorvastatin group, fasting and 2-h 
postprandial blood glucose concentrations increased 
significantly by 7.57% and 3.59% respectively after 
the study intervention. By contrast, in the RBO group, 
the fasting and 2-h postprandial blood glucose 
concentrations decreased significantly by 8.06% and 
14.79% respectively after the study intervention. 
HbA1C increased significantly by 6.27% after the study 
intervention in the Atorvastatin group. However, 
HbA1C was significantly reduced by 8.13% after the 
study intervention than before the intervention in the 
RBO group. 
Atorvastatin and RBO groups showed 
significant reduction in serum TC concentrations 
(mean changes: 24.05% and 16.49%, respectively), 
TG concentrations (mean changes: 28.55% and 
12.91% respectively), LDL-C concentrations (mean 
changes: 31.41% and 18.64% respectively), and the 
atherogenic ratio of TC/HDL-C ratio (mean changes: 
30.62% and 25.15%, respectively) from baseline.  
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Table 3: Blood glucose, HbA1C and serum lipid levels in subjects before and after intervention periods either with Atorvastatin or 
RBO. 
1,2,3 
      RBO (n =22)          Parameters                                                                         Atorvastatin (n =22)                                               
Change(%)       After 6 Months       Baseline Change(%)        After 6 months         Baseline  
6438-  138.91 ± 3.25* 151.09 ± 3.52 7.57 171.64 ± 1.86* 150.27 ± 1.87 Fasting blood glucose (mg/dL) 
9.441-  223.01 ± 8.3* 256.21 ± 7.5 0451 245403 ± 6.3* 258493 ± 5.5 PP blood glucose(mg/dL)  
6490-  7.80 ± 0.29* 8.49 ± 0.28 8424 8.13 ± 0.28* 7.65 ± 0.25 HbA1C 
4
 (%)  
984.1-  
#
 196.82 ± 2.09* 235.68 ± 2.52 2.435-  180.32 ± 3.08* 237.45 ± 3.60 TC 
5 
(mg/dL) 
92419-  
#
 196.32 ± 3.39* 225.41 ± 3.53 26455-  162.86 ± 6.38* 227.95 ± 4.91 TG 
5
 (mg/dL) 
0418 31.00 ± 0.88 29.82 ± 0.99 054.2-  25.36 ± 1.03* 39.27 ± 1.46 VLDL-C 
5
 (mg/dL) 
9648- 4 
#
 120.82 ± 2.55* 148.50 ± 2.30 094.9-  100.36 ± 2.77* 146.32 ± 2.43 LDL-C
 5
 (mg/dL) 
99488 39.64 ± 1.18* 35.50 ± 1.06 1452 37.73 ± 1.02* 34.45 ± 1.06 HDL-C 
5
 (mg/dL) 
25495-  .414 ± 0.83* 6.64 ± 1.66 03482-  4.78 ± 0.92* 6.89 ± 1.72 TC/HDL-C
5 
ratio 
 
1Values are expressed as means ±SEM. 2 Values with asterisk (*) are significantly different from baseline values (p < 0.05). 3 Values with sharp (#) are significantly different from 
Atorvastatin group (p < 0.05). 4 HbA1C glycosylated hemoglobin. 5 TC, total cholesterol; TG, triglyceride; VLDL-C, very low density lipoprotein; LDL-C, low density lipoprotein; HDL-C, 
high density lipoprotein; TC/HDL-C, ratio of total cholesterol to HDL-C. 
 
 
By contrast, HDL-C concentrations showed 
significant increase in atorvastatin and RBO groups 
(mean changes: 9.52% and 11.66%, respectively) 
from baseline. 
In the atorvastatin group, VLDL-C decreased 
by 35.42% after the study intervention. In the RBO 
group, VLDL-C increased by 3.96% but the change 
was not significantly different after the study 
intervention. 
A comparison of the percentage change in 
TC, TG and LDL before and after the study 
intervention showed a significant difference in their 
levels between RBO group and atorvastatin group. 
As shown in Table 4, the activity of ALT and 
AST were normal and almost the same in both 
atorvastatin and RBO groups at baseline. After 6 
months of intervention of atorvastatin, it resulted a 
significant increase in ALT and AST activity by 
35.34% and 51.40% respectively but it remained 
almost unchanged in RBO group. Serum level of 
creatinine showed non-significant change in both 
groups before and after the study intervention. Urea 
levels showed non-significant change in atorvastatin 
group, while it showed a significant decrease of 
14.49% in RBO group. A significant reduction in 
serum uric acid levels was shown in atorvastatin and 
RBO groups of 9.46% and 18.13% respectively after 
the study intervention. 
Erythrocyte sedimentation rate (ESR) showed 
significant decrease of 28.00% and 31.11% during the 
first and second hour respectively in atorvastatin 
group. Similarly in the RBO group, ESR showed a 
significant decrease of 36.17% and 40.86% during the 
first and second hour respectively.   
Discussion 
Individuals with type 2 diabetes mellitus 
(T2DM) have an increased risk of mortality, primarily 
because of cardiovascular disease (CVD). An 
important risk factor for the development of CVD is 
dyslipidemia. Many studies have shown that lipid 
lowering treatments reduce the risk of CVD and death. 
Most of the hypolipidemic drugs, currently in 
use in the treatment of dyslipidemia in type 2 
diabetics, have a plenty of side effects [25] and this 
has further necessitated the search for suitable 
alternatives. In contrast, natural source as rice bran oil 
has a hypoglycemic effect [26], effective lipid lowering 
property [27], in addition to its potent antioxidant 
activity [28]. The aim of this study was to compare the 
effects of atorvastatin vs RBO on blood glucose, 
serum lipid profiles and their safety in type 2 diabetic 
patients. Atorvastatin drug was chosen in our study as 
it is the most commonly used drug for treatment of 
hypercholesterolemia in Egypt. 
Atorvastatin is frequently administered for the 
treatment of dyslipidemia associated with type 2 
diabetes mellitus, and used for primary prevention of 
major cardiovascular events [29]. However, a marked 
deterioration of glycemic control has been reported in 
patients with diabetes following atorvastatin therapy 
for 3 to 4 months in Japanese diabetic patients [30]. 
The current study, in agreement with earlier 
reports manifested a significant elevation of HbA1C 
level in patients treated with atorvastatin [31]. This 
was accompanied by increased fasting [32] and two 
hour postprandial blood glucose levels [33, 34].  
 
 
Table 4: Liver and kidney function tests of Atorvastatin and RBO groups. 
1,2,3
 
      Parameters            Atorvastatin (n =22)                                                                                    RBO (n =22) 
                                                                                                                               
Change(%) After 6 months Baseline Change(%) After 6 months Baseline  
-2.98 35.14 ± 1.55  ± 1.2608422 0540.  ± 1.99*53402  ± 0.9504496 ALT (U/L)
4
 
-2.59  ± 1.220.422 35.13 ± 0.68 594.3  ± 3.08*55435  ± 0.7108408 AST (U/L)
5
 
0421 - ± 0.293466 0.91 ± 0.30 9942. - ± 0.243441 0.89 ± 0.03 Serum Creatinine (mg/dL) 
#
 9.4.1-  ± 0.71*0948.  ± 0.8204433 2458 - ± 2.106  ± 1.601 Blood Urea (mg/dL) 
#
 96490-  ± 0.18*5481 6.95 ± 0.18 14.8 - ± 0.13*84.9  ± 0.124436 Serum uric acid (mg/dL) 
#
 08494 -
#
 .3468 -
30 ± 1.33*
 
 ± 1.86* 55 
 ± 1.23.4 
 ± 0.9610 
-28.00 
09499- 
 ± 2.6*08 
 ± 3.4*82 
 ± 2.253 
 ± 2.913 
ESR
6
 
First hour (mm/hr) 
Second hour (mm/hr) 
 
1
Values are expressed as means ±SEM. 
2
 Values with asterisk (*) are significantly different from baseline values (p < 0.05). 
3
 Values with sharp (
#
) are significantly different from 
Atorvastatin group (p < 0.05). 
4
 ALT, alanine transaminase. 
5
 AST, aspartate transaminase,
 6
ESR, Erythrocyte Sedimentation Rate. 
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Because HbA1C levels are a sensitive 
indicator for glycemic control, our results strongly 
suggest that atorvastatin causes glucose intolerance 
that may lead to decreased insulin sensitivity and 
modestly increase the risk of developing diabetes 
mellitus [35]. These baneful metabolic effects of 
atorvastatin occur despite its beneficial effect to 
improve lipid profile.  
In the contrary, a significant reduction of 
HbA1C level was shown in RBO goup. This was also 
accompanied by a significant decrease in fasting and 
two hour postprandial blood glucose levels. According 
to our results, we found that there is an appreciable 
amount of oleic acid in RBO which could be the cause 
of blood glucose reduction. Our results are in 
accordance with previous studies that emphasized the 
role of monounsaturated fatty acids content of RBO in 
decreasing postprandial plasma glucose, increasing 
insulin sensitivity and suppressing the 
hyperinsulinemic response in rats with T2DM [36, 37, 
38]. 
Tocotrienol rich fraction (TRF) in rice bran oil 
(RBO) has also been shown to lower the blood 
glucose level in patients and preclinical animal models 
[26].  Further TRF may be a useful antioxidant 
effectively caused decrease in glycosylated 
hemoglobin (HbA1C) in diabetic rats [39]. 
Furthermore, Oryzanol content in RBO can be 
considered as a novel antinociceptive agent and can 
be used as a possible therapeutic option in the 
treatment of neuropathic pain associated with 
diabetes mellitus [40]. 
In our present study, we speculated that the 
improvement of the glycemic status in RBO group 
may have been resulted from the high MUFA and 
tocotrienol content in RBO. RBO could therefore 
provide a new adjuvant therapeutic line for better 
control of diabetes. 
The most common lipid abnormalities in 
diabetes are hypertriglyceridemia and 
hypercholesterolemia [41]. Atorvastatin was used in 
this study in order to understand how far RBO 
hypolipdemic effect is comparable to that drug. 
Atorvastatin and RBO were evaluated for their anti-
hyperlipidemic activity by estimating serum 
triacylglyceride (TG), total cholesterol (TC), very low 
density lipoprotein-cholesterol (VLDL), low-density 
lipoprotein cholesterol (LDL) and high-density 
lipoprotein-cholesterol (HDL) levels.  
In the present study, both atorvastatin and 
RBO signiﬁcantly improved the lipid proﬁle, each in 
different aspects, in groups of patients with type 2 
diabetes. 
RBO and its specific components 
(unsaturated fatty acids, triterpene alcohols, 
phytosterols, tocotrienols, alpha-tocopherol and γ- 
oryzanol) have been shown by many studies to have 
an effect on lipid metabolism [42]. RBO  improves the 
plasma lipid pattern of rodents, rabbits, non-human 
primates and humans, reducing total plasma 
cholesterol, triglyceride concentration and increasing 
the high density lipoprotein cholesterol level [43, 10]. 
The amount of linoleic acid in RBO is rather 
moderate among the vegetable oils (36.58% of total 
fatty acids), but it is still a rich source. RBO also 
contains a relatively high proportion of oleic acid 
(41.46%). Conjugated linoleic acid (CLA) and oleic 
acid have been shown to offer a host of beneficial 
benefits for the body. They can regulate blood glucose 
levels and serum lipids, help to lose weight, prevent 
cardiovascular disease, lower high blood pressure 
and reduce inflammation [44, 45]. These results are 
supported by the recommendation of the American 
Diabetes Association that patients with type 2 
diabetes should consume vegetable oil containing 
abundant amounts of oleic acid to improve 
hyperlipidemia and prevent heart related diseases [46, 
47]. RBO also contains a detectable amount of a 
linolenic acid 1 .29%. This amount may be enough to 
increase the content of (n-3) highly polyunsaturated 
fatty acids such as eicosapentaenoic and 
docosahexaenoic acids in tissue phospholipids 
compared with other vegetable oils [48]. 
Many researchers have implicated the rich 
unsaponifiable compounds of the RBO mainly 
composed of sterols such as γoryzanol, triterpene 
alcohols and tocotrienols as being responsible for its 
hypolipidemic effect [49], as well as for its 
antiatherogenic property [50]. 
The reduction in the TC and LDL level by 
RBO may be associated with the presence of 
phytosterols which act either by influencing the 
absorption of dietary cholesterol from the gut or 
enhancing the conversion of cholesterol to fecal bile 
acids [10]. The presence of γ-oryzanol (cycloartenol), 
a ferulate ester of triterpene alcohol with a similar 
structure to cholesterol, may compete with the binding 
sites of cholesterol, thereby impaired uptake of 
cholesterol into enterocytes by withdrawal cholesterol 
from the system [51].  Oryzanol has an effect on 
lowering plasma non-HDL-C and raising plasma HDL 
through a greater extent to increase fecal excretion of 
cholesterol and its metabolites [1].   
Moreover, tocotrienols, one of the essential 
components of RBO have been suggested to lower 
TC concentrations in the blood, thought inhibiting the 
HMG-CoA reductase activity in the biosynthetic 
pathway of cholesterol [52]. Many studies indicate that 
tocotrienols have cardioprotective properties in 
humans [53] by improving postischemic ventricular 
function and reducing myocardial infarct size [54]. 
Furthermore, the reduction in the TC level by RBO 
may be due to the presence of high amount of Oleic 
acid which belongs to the class of MUFAs [55]. 
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  The reduction in the TG level by RBO may be 
associated with the presence of triterpene alcohols 
and phytosterols which lower the circulating levels of 
cholesterol and TG due to the possible structural 
similarity of cycloartenol and cholesterol [56]. Another 
probable mechanism may involve an increase in the 
lipoprotein lipase (LPL) enzyme which is capable of 
breaking down plasma TGs of TG-rich lipoproteins, 
including chylomicrons and VLDL [57]. Furthermore, 
our study shows that RBO has the ability to reduce 
the atherogenic ratio of TC / HDL-C concentration to a 
great level (25.15%). This finding is in agreement with 
the earlier reports [58, 59]. 
Statins are highly effective cholesterol-
lowering agents, and have been shown to reduce 
atherosclerosis-related mortality in patients with 
diabetes [60]. 
Atorvastatin is a potent inhibitor of 
hydroxymethylglutaryl-CoA reductase, which 
decreases all major LDL subspecies in plasma by 
upregulating LDL receptor activity [61]. Atorvastatin 
also reduces the secretion of apo B. This is believed 
to account for its TG-lowering effect, which is more 
profound at higher doses [62]. 
Hepatic dysfunction is a risk factor for statins 
as the predominant route of elimination for the 
majority of this class of drugs occurs via the bile after 
metabolism by the liver [63]. 
In the present study, ALT and AST elevations 
occurs in diabetic patients by 6 months drug 
intervention of atorvastatin. Many studies confirm our 
results [64]. Therefore, despite the beneficial effect of 
atorvastatin in achieving significant levels of TC, LDL 
cholesterol reduction and significant level of  HDL 
cholesterol elevation , it may lead in some cases to a 
hepatotoxic effect  as occurs with high atorvastatin 
doses (80 mg/kg), whereas the lower dose (20 mg/kg) 
seems to cause mild liver injury [65]. Moreover, 
atorvastatin may induce pancreatitis [66] and 
cholestasis [67]. Statin-associated myalgia is an 
important clinical problem that will likely become more 
prevalent owing to the ever-expanding indications for 
statin use [68]. In general, statins are well tolerated 
and serious adverse events including muscle toxicity 
are rare [69]. 
Serum creatinine was not significantly 
affected in diabetic patients receiving atorvastatin in 
our study. Same results have been shown in a 
previous study [70].   
Epidemiological studies confirmed a positive 
association between raised SUA levels and risk of 
CHD or CVD in the general population [71].  Our 
results showed that atorvastatin significantly lowered 
serum uric acid levels. It exerts a hypouricemic action 
by affecting uric acid metabolism [72].   
In the present study, atorvastatin induced 
reduction in erythrocyte sedimentation rate (ESR). A 
previous study provided evidence that atorvastatin 
has fast and early anti-inflammatory effects [73]. 
Similarly, our findings demonstrate that RBO reduced 
ESR. Scientific research suggests that Phytosterols 
and linoleic acid content in RBO provide antioxidant 
and anti-inflammatory effects [74]. 
Furthermore, our results showed that blood 
urea nitrogen level was significantly lowered in 
diabetic patients by 6 months dietary intervention 
involving consumption of RBO. Same results have 
been previously demonstrated by [75]. 
In conclusion, it could be suggested that the 
6-months dietary intervention involving consumption 
of RBO, has advantages in terms of lowering fasting 
and postprandial blood glucose, suppressing serum 
lipid levels and improving the cardiovascular risk 
profile. Some components of RBO, possibly in the 
unsaponifiable fraction, may have exerted a greater 
effect on plasma lipids relative to other vegetable oils 
than can be ascribed to the fatty acid composition of 
the oil itself. Our findings show that RBO and 
atorvastatin exert similar and substantially beneficial 
effects on serum lipid profile, significant reduction of 
TC, TG, LDL cholesterol and TC / HDL-C ratio levels 
and increase in HDL cholesterol level, coupled with a 
hypouricemic action and anti-inflammatory effects. 
Despite beneficial improvement in lipid profile, 
atorvastatin treatment resulted in significant increase 
in blood glucose and glycosylated hemoglobin levels. 
Furthermore, it may induce in some cases a 
hepatotoxic effect, pancreatitis and cholestasis as it 
may occur with high atorvastatin doses or its 
consumption for long term. The use of rice bran oil 
together with dietary and lifestyle modifications may 
have implications for reducing the risk of 
cardiovascular disease. Therefore, the findings 
obtained from the current study reinforce the use of 
RBO as a natural potent hypolipidemic agent in type 2 
diabetic patients safer than atorvastatin drug. 
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